摘要
甲状腺相关性眼病(thyroid-associated ophthalmopathy,TAO)是发病率高、发病机制不明的主要眼病之一,也是严重危害视力的重要病因之一。它已然影响到大部分甲亢患者的日常生活,使其生活质量直线下降,已引起内分泌科、眼科、核医学科等多个医学领域研究人员及临床医师关注。目前其发病机制仍未完全清楚,疗效也未达百分百满意,随着探索发病机制,治疗方案越来越多,除去经典的糖皮质激素治疗方案,多种免疫抑制剂、靶向、放疗、外科手术,甚至联合疗法等已在临床得以应用。各种治疗手段各有优缺点,本文对TAO治疗进展展开综述。
Thyroid-associated ophthalmopathy is one of the main ophthalmopathy with high incidence and unknown pathogenesis,and it is also one of the important etiologies that can seriously harm vision.It has already affected the daily life of most patients with hyperthyroidism and caused a linear decline in their quality of life,which has attracted the attention of researchers and clinicians in many medical fields such as endocrinology,ophthalmology,and nuclear medicine.At present,the pathogenesis is still not completely clear and the efficacy is not 100%satisfactory.With the exploration of the pathogenesis,the treatment schemes are increasing day by day.Besides the classical glucocorticoid treatment schemes,a variety of immunosuppressants,targeted therapy,radiotherapy,surgery,and even combined therapy have been used in clinic one after another.There are advantages and disadvantages of various treatment methods.This article reviews the progress of TAO treatment.
作者
舒杨
熊加红
沙永红
SHU Yang;XIONG Jiahong;SHA Yonghong(Jishou University School of Medicine,Jishou 416000,China)
出处
《中国医学创新》
CAS
2022年第27期180-184,共5页
Medical Innovation of China
